Netherlands· NL-149749ffe41f

Vydura 75 mg, lyofilisaat voor oraal gebruik

A rimegepant product containing rimegepanthemisulfaat 1,5-water, registered in Netherlands by Pfizer Europe MA EEIG. The same ATC class is registered in 16 of our 19 countries.

ATC N02CD06

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about rimegepanthemisulfaat 1,5-waterAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Rimegepant is registered in 16 of 19 countries.

Countries holding a registration under ATC N02CD06 (rimegepant), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
11 of them publish a price we can compare per daily dose

Search rimegepant products by name

Rimegepant · ATC N02CD06

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Italyprice
Netherlands
Norwayprice
Polandprice
Spainprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rimegepant costs, country by country.

Normalised to the WHO defined daily dose (37.5 mg), the median price runs from $14.84 in Switzerland to $64.33 in United States — a ×4.3 gap.

4 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown
US figures are pharmacy acquisition cost (CMS NADAC), not retail

Open the full comparison — free account Drug prices for market access

Rimegepant · price per daily dose (37.5 mg)

USD · FX 28 Sept 2026

US United States$64.33 (acquisition cost)
IT Italy$18.89
ES Spain$16.29
CH Switzerland$14.84

Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: RIMEGEPANTHEMISULFAAT 1,5-WATER
Manufacturer: Pfizer Europe MA EEIG
Country: Netherlands (NL)
ATC code: N02CD06
ATC class: Rimegepant
Defined daily dose: 37.5 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/22/1645

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

90 interactions on record for rimegepant.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check rimegepant against other medicines How interaction checks work

Rimegepant · interactions on record

90 records

9 severe
81 moderate

Most severe, free to view

DexamethasoneH02AB02severe
DabrafenibL01EC02severe
LorlatinibL01ED05severe
DabrafenibL01XE23severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rimegepant in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rimegepant products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Vydura
Liechtenstein · Vydura
Norway · Vydura

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/8de93d25-1f40-4a24-8910-bf5cd43354f9
GET /v1/drugs/8de93d25-1f40-4a24-8910-bf5cd43354f9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Lyofilisaat voor oraal gebruik",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/vydura-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Rimegepant",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128013",
  "excipients": [
    "BENZYLALCOHOL (E 1519)",
    "EUCALYPTOL",
    "GELATINE (E 441)",
    "LEVOMENTHOL",
    "LIMONEEN (D (+) VORM)",
    "MALTODEXTRINE",
    "MANNITOL (D-) (E 421)",
    "MENTHON (L-Vorm)",
    "MENTHYLACETAAT",
    "PEPERMUNTSMAAKSTOF 51.296 TP 0551",
    "SUCRALOSE (E 955)",
    "VANILLINE"
  ],
  "substances": [
    "RIMEGEPANTHEMISULFAAT 1,5-WATER"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/04/25",
  "procedure_number": "EMEA/H/C/005725",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/22/1645",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about rimegepant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console